Biomics Biopharma

The company is managed by a professional team which is consisted with several oversea returnees. Over 60% of employees are with college degrees or above, including over 20 PhDs and Masters. Biomics owns 16.6 acre land including 10000 m2 well-equipped R&D facility and possesses a comprehensive RNAi drug developing platforms comprised of Entire siRNA Targets Library, High-throughput Screening, Large-scale Synthesis, siRNA Delivery System and in-vivo Evaluation System. In addition, the company owns over 40 national and international patents. Meanwhile, company possesses a pipeline with several ongoing programs for the treatments of Age-related Macular Degeneration (AMD), Hepatitis B, Bladder Cancer and other serious diseases. In 2009, first RNAi based product was launched by Genecon Biotech, a subsidiary of Biomics, for use of depigmentation. AMD candidate developed by Biomics scientists was successfully launched to pre-clinical stage which. It is not only an excellent validation of the company's sophisticated technologies, but also a strong statement of the researchers' capabilities. With the boost of Biomics in the last five years, in 2011, the company was selected as a national RNAi base. Additionally, Biomics has collaborative and partnership agreements with leading institutes worldwide, including Peking University, Benitec Biopharma (Australia) and Zetiq Technologies (Israel).